glp-1 agonists pills New Guidelines for Type 2 Diabetes in 2025 and stomach upset GLP-1 Medications and Birth Control

Insurance almost never covers wellness IV therapy , but many HSA and FSA accounts will reimburse costs

Neuropathic pain: mechanism-based therapeutics

doi:10.3389/fmed.2021.636924 14Kumar R, Das A, Das S

Who responds best to CagriSema Ideal candidates: Significant obesity (BMI 30-40+) Previously plateaued on GLP-1s alone Need maximum weight loss Good GI tolerability Metabolic syndrome or diabetes Commitment to long-term use Excellent responders: Higher baseline weight (more to lose) Good adherence to protocol Combine with diet/exercise Younger patients (better metabolism) No significant medication interactions May respond less optimally: Very low starting weight (BMI 30%): Nausea (most common) Decreased appetite (intended effect) Constipation Fatigue (especially first months) Common (10-30%): Vomiting (if nausea not managed) Diarrhea (alternating with constipation) Abdominal pain/discomfort Headache Dizziness Less common ( 40 with comorbidities Insurance covers surgery Want permanent solution Don't want ongoing injections Sourcing cagrilintide and semaglutide Obtaining these peptides requires understanding current availability

This indicated a lower influx of proline into the TCA cycle via the glutamate to -ketoglutarate route